Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Nov 5, 2024
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Older --
Read more at globenewswire.com
